HRCT Useful In Sclerodermal Lung Disease Treatment PDF Print E-mail
Thursday, 26 November 2009 10:46
In a recent Reuters Health article, it was reported that the serial scanning of the thorax with high-resolution computed tomography (HRCT) is useful for monitoring the response of Sclerodermal lung disease to therapy, according to a further report in the November Chest.

The report focused on 98 patients with sclerodermal-interstitial lung disease who had completed one year of treatment with either cyclophosphamide or placebo in a randomized Scleroderma Lung Study. According to senior author Dr. Donald P. Tashkin, from the University of California, the cyclophosphamide produced significant improvements in pulmonary function and symptoms. Dr. Tashkin, and his colleagues also compared parenchymal abnormalities between baseline and follow-up HRCT scans.

Amongst the 49 patients in the cyclophosphamide arm, 14 had worse fibrosis scores at 12 months and 35 had scores that were not worse. In contrast, among the 49 patients in the placebo group, 26 had worse fibrosis scores at 12 months and 23 had scores that were not worse.

HRCT fibrosis scores correlated with pulmonary function and skin thickness scores, the investigators said, and changes in dyspnea over time showed moderate correlations with changes in fibrosis.

"Our findings provide a rationale for performing follow-up HRCT scans in patients with scleroderma interstitial lung disease undergoing treatment with oral cyclophosphamide or some other potentially active agent as a means of assessing the patient's response to therapy and determining whether additional treatment is needed in patients with HRCT evidence of progressive fibrosis despite their existing therapy," Dr. Tashkin told Reuters Health.

"HRCT scans provide an objective method of assessing changes in both inflammation and fibrosis in the lungs of patients with interstitial lung disease," he added. "They therefore provide a useful complement to measured changes in lung physiology."

For a link to the full and original article, click here.
 
More articles :

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» TLR4 Protein Implicated In The Fibrosis Associated With Scleroderma

An international multi-disciplinary research team led by scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.Recently reported in the , this finding has implications for...

» Venus Goes Vegan To Combat Sjogren’s Syndrome

was diagnosed with , an autoimmune disorder, after experiencing unusual fatigue for years. Sjogren’s currently has no cure, so patients are typically put on regimens to try and manage it. In some cases, the condition can progress to cause kidney...

» Our First Year Anniversary

Celebrating an important anniversary is always a blessing. The Scleroderma Care Foundation was officially incorporated on 15th October 2008. Its mission to provide support and education for persons afflicted with within Trinidad and Tobago became a...

» Important Information On Flaxseed And Flaxseed Oil

Flaxseed, called linseed in some countries, is a good source of dietary fiber, , and . Each of these components may contribute to the health effects of eating flaxseed, but flaxseed oil contains no fiber and very little lignan. In addition to its...

» Egr-1: A Target for Scleroderma Therapy

Two separate research groups funded by the (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue...